OKYO Pharma Limited (OKYO)
Largest Insider Buys in Sector
OKYO Stock Price History Chart
OKYO Stock Performance
About OKYO Pharma Limited
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Insider Activity of OKYO Pharma Limited
Over the last 12 months, insiders at OKYO Pharma Limited have bought $0 and sold $0 worth of OKYO Pharma Limited stock.
On average, over the past 5 years, insiders at OKYO Pharma Limited have bought $381,278 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 16,670 shares for transaction amount of $25,005 was made by BRANCACCIO JOHN P (director) on 2023‑09‑15.
List of Insider Buy and Sell Transactions, OKYO Pharma Limited
| 2023-09-15 | director | 16,670 0.0722% | $1.50 | $25,005 | -25.13% | |||
| 2022-05-19 | Non-Executive Chairman | 5.84M 1.7068% | $0.10 | $590,800 | -36.04% | |||
| 2022-05-19 | Chief Executive Officer | 12,500 0.1445% | $4.00 | $50,000 | -36.04% | |||
| 2022-05-17 | Non-Executive Chairman | 25,000 0.2795% | $3.87 | $96,750 | -40.88% |
Insider Historical Profitability
| CERRONE GABRIELE M | Non-Executive Chairman | 548981215 1620.0677% | $1.07 | 2 | 0 | <0.0001% |
| BRANCACCIO JOHN P | director | 16670 0.0492% | $1.07 | 1 | 0 | <0.0001% |
| JACOB GARY S | Chief Executive Officer | 12500 0.0369% | $1.07 | 1 | 0 | <0.0001% |